LLY

1,007.5

-0.79%↓

JNJ

230.78

+0.16%↑

ABBV

210.82

+1.12%↑

UNH

398.96

-0.39%↓

AZN

184.93

-1.48%↓

LLY

1,007.5

-0.79%↓

JNJ

230.78

+0.16%↑

ABBV

210.82

+1.12%↑

UNH

398.96

-0.39%↓

AZN

184.93

-1.48%↓

LLY

1,007.5

-0.79%↓

JNJ

230.78

+0.16%↑

ABBV

210.82

+1.12%↑

UNH

398.96

-0.39%↓

AZN

184.93

-1.48%↓

LLY

1,007.5

-0.79%↓

JNJ

230.78

+0.16%↑

ABBV

210.82

+1.12%↑

UNH

398.96

-0.39%↓

AZN

184.93

-1.48%↓

LLY

1,007.5

-0.79%↓

JNJ

230.78

+0.16%↑

ABBV

210.82

+1.12%↑

UNH

398.96

-0.39%↓

AZN

184.93

-1.48%↓

Начало・Списък с акции・MacroGenics Inc

MacroGenics Inc

Затворен

СекторЗдравеопазване

4.15 19.6

Купи Продай

Преглед

Промяна на цената на акция

24 ч

Текуща

Минимум

3.43

Максимум

4.3

Ключови измерители
By Trading Economics
Приходи	-31M -14M
Продажби	-32M 41M
EPS	-0.22
Марж на печалбата	-34.333
Служители	293
EBITDA	-37M -15M

Препоръки
By TipRanks
Препоръки	Купи
12-месечна прогноза	+83.48% upside

Дивиденти
By Dow Jones
Следващи печалби	19.05.2026 г.

Пазарни показатели
By TradingEconomics
Пазарна капитализация	65M 188M
Предишно отваряне	-15.45
Предишно затваряне	4.15

Настроения в новините

By Acuity

35%

65%

112 / 346 Класиране в Healthcare

Техническа оценка

By Trading Central

Увереност

Neutral Evidence

1.47 / 1.64 Подкрепа & съпротива

MacroGenics Inc Графика

Миналото представяне не гарантира бъдещи резултати.

Свързани новини

14.05.2026 г., 22:44 ч. UTC

Придобивния, сливания и поглъщания

LVMH to Sell Marc Jacobs Fashion Brand to WHP, G-III Apparel -- 2nd Update

14.05.2026 г., 22:27 ч. UTC

Придобивния, сливания и поглъщания

LVMH Selling Marc Jacobs Fashion Brand to WHP, G-III Apparel -- Update

14.05.2026 г., 22:12 ч. UTC

Печалби

Applied Materials Raises Outlook as Semiconductor Equipment Demand Grows -- 2nd Update

14.05.2026 г., 21:52 ч. UTC

Придобивния, сливания и поглъщания

LVMH to Sell Marc Jacobs

15.05.2026 г., 00:00 ч. UTC

Печалби

Honda's Never Faced a Crisis Like This -- And a Comeback Won't Be Easy -- WSJ

14.05.2026 г., 23:57 ч. UTC

Придобивния, сливания и поглъщания

Kakao: Stake Sales Aim to Secure Funds for Future Investments

14.05.2026 г., 23:56 ч. UTC

Придобивния, сливания и поглъщания

Kakao: Share Sale to Lower Kakao Investment's Stake in Dunmau to 4.03%

14.05.2026 г., 23:56 ч. UTC

Придобивния, сливания и поглъщания

Kakao: Affiliate Kakao Investment to Sell 2.3M Dunamu Shares on June 15

14.05.2026 г., 23:56 ч. UTC

Пазарно говорене

Gold Prices Rise on Strong Demand -- Market Talk

14.05.2026 г., 23:56 ч. UTC

Придобивния, сливания и поглъщания

Kakao to Sell 6.55% Stake in Crypto Exchange Operator Dunamu to Hana Financial for KRW1.003T

14.05.2026 г., 23:50 ч. UTC

Пазарно говорене

Global Equities Roundup: Market Talk

14.05.2026 г., 23:50 ч. UTC

Пазарно говорене

Nikkei May Rise as AI Enthusiasm Continues -- Market Talk

14.05.2026 г., 23:47 ч. UTC

Печалби

JSW Steel: Prolonged Supply-Chain Disruptions Due to Middle East Crisis Pose Risk to Growth >500228.BY

14.05.2026 г., 23:47 ч. UTC

Печалби

JSW Steel Results Supported by Higher Steel Prices, One-Off Divestment Gains >500228.BY

14.05.2026 г., 23:46 ч. UTC

Печалби

JSW Steel 4Q Net INR163.7B Vs. Net INR21.39B >500228.BY

14.05.2026 г., 23:46 ч. UTC

Печалби

JSW Steel 4Q Rev INR511.8B Vs. INR448.19B >500228.BY

14.05.2026 г., 23:28 ч. UTC

Пазарно говорене

New Zealand's Economy Faltering Amid Shocks -- Market Talk

14.05.2026 г., 23:00 ч. UTC

Пазарно говорене

Australia's One Nation Party Leads In The Polls -- Market Talk

14.05.2026 г., 22:46 ч. UTC

Пазарно говорене

Global Equities Roundup: Market Talk

14.05.2026 г., 22:46 ч. UTC

Пазарно говорене

Court Decision 'Negative But Balanced' for Coles -- Market Talk

14.05.2026 г., 22:46 ч. UTC

Пазарно говорене

Global Forex and Fixed Income Roundup: Market Talk

14.05.2026 г., 22:35 ч. UTC

Пазарно говорене

Fed's Warsh Talks Big Game; Will Focus On Credibility First -- Market Talk

14.05.2026 г., 22:11 ч. UTC

Придобивния, сливания и поглъщания

LVMH Agrees to Sell Marc Jacobs -- WSJ

14.05.2026 г., 22:06 ч. UTC

Пазарно говорене

Applied Materials Gets Improved Visibility into Customer Orders -- Market Talk

14.05.2026 г., 22:04 ч. UTC

Печалби

Thai Beverage Results Supported by Higher Contributions From Spritis Business >Y92.SG

14.05.2026 г., 22:04 ч. UTC

Печалби

Thai Beverage 2Q Net THB7.37B Vs. Net THB6.74B >Y92.SG

14.05.2026 г., 22:04 ч. UTC

Печалби

Thai Beverage 2Q Rev THB86.52B Vs. THB85.35B >Y92.SG

14.05.2026 г., 22:00 ч. UTC

Печалби

Xanadu Quantum Revenue Increases Fourfold. Why the Stock Is Falling. -- Barrons.com

14.05.2026 г., 21:55 ч. UTC

Печалби

Nu Holdings 1Q EPS 18c >NU

14.05.2026 г., 21:55 ч. UTC

Печалби

Nu Holdings 1Q Rev $4.97B >NU

Сравнение с други в отрасъла

Ценова промяна

MacroGenics Inc Прогноза

Ценова цел

By TipRanks

83.48% нагоре

12-месечна прогноза

Среден 6.33 USD 83.48%

Висок 9 USD

Нисък 4 USD

Според 5 анализатори от Wall Street, предложили 12-месечна ценова цел за MacroGenics Inc през последните три месеца.

Консенсусна оценка

By TipRanks

Купи

5 ratings

Купи

Задържане

Продай

Според 5 анализатори, дали борсови рейтинги на MacroGenics Inc през последните 3 месеца.

Техническа оценка

By Trading Central

1.47 / 1.64Подкрепа & съпротива

The bullish and bearish events are balanced.

Recent bullish events outweigh bearish events.

All events are bearish.

Настроение

By Acuity

112 / 346 Класиране в Здравеопазване

Финанси

Продажбени и админисративни разходи

Оперативни разходи

Печалба преди облагане с данъци

Продажби

Разходи за продажби

Брутна печалба от продажби

Разходи за лихви по дълг

EBITDA

Оперативна печалба

Относно MacroGenics Inc

MacroGenics, Inc., a biopharmaceutical company, develops, manufactures, and commercializes antibody-based therapeutics to treat cancer in the United States. Its approved product is MARGENZA (margetuximab-cmkb), a human epidermal growth factor receptor 2 (HER2) receptor antagonist indicated, in combination with chemotherapy, for the treatment of adult patients with metastatic HER2-positive breast cancer who have received two or more prior anti-HER2 regimens. The company's pipeline of immuno-oncology product candidates includes MGC018, an antibody drug conjugate (ADC), which targets solid tumors expressing B7-H3; Enoblituzumab, a monoclonal antibody that targets B7-H3; and MGD024, an investigational bispecific CD123 × CD3 DART molecule to minimize cytokine-release syndrome for patients with hematologic malignancies. In addition, it develops Lorigerlimab, a monoclonal antibody that targets the immune checkpoints PD-1 and cytotoxic T-lymphocyte-associated protein 4; Tebotelimab, an investigational tetravalent DART molecule for PD-1 and lymphocyte-activation gene 3; Retifanlimab, a humanized monoclonal antibody targeting programmed death receptor-1; and IMGC936, an ADC that targets ADAM9, a cell surface protein over-expressed in various solid tumor types. Further, the company develops MGD014 and MGD020, a DART molecule to target the envelope protein of human immunodeficiency virus infected cells and CD3 on T cells; Teplizumab for the treatment of type 1 diabetes; and PRV-3279, a CD32B × CD79B DART molecule for the treatment of autoimmune indications. It has collaborations with Incyte Corporation; Zai Lab Limited; I-Mab Biopharma; and Janssen Biotech, Inc. The company was incorporated in 2000 and is headquartered in Rockville, Maryland.